WO1996039810A1 - Human hepatocellular tissue in chimeric immunocompromised animals - Google Patents
Human hepatocellular tissue in chimeric immunocompromised animals Download PDFInfo
- Publication number
- WO1996039810A1 WO1996039810A1 PCT/EP1996/002456 EP9602456W WO9639810A1 WO 1996039810 A1 WO1996039810 A1 WO 1996039810A1 EP 9602456 W EP9602456 W EP 9602456W WO 9639810 A1 WO9639810 A1 WO 9639810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- host
- hepatocytes
- human
- cells
- organ
- Prior art date
Links
- 206010061598 Immunodeficiency Diseases 0.000 title claims abstract description 20
- 241001465754 Metazoa Species 0.000 title abstract description 23
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 107
- 210000004185 liver Anatomy 0.000 claims abstract description 44
- 210000000056 organ Anatomy 0.000 claims abstract description 24
- 244000052769 pathogen Species 0.000 claims abstract description 23
- 239000003102 growth factor Substances 0.000 claims abstract description 18
- 239000000725 suspension Substances 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims abstract description 12
- 208000006454 hepatitis Diseases 0.000 claims abstract description 7
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 37
- 208000015181 infectious disease Diseases 0.000 claims description 27
- 238000002347 injection Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 22
- 230000002440 hepatic effect Effects 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 230000001717 pathogenic effect Effects 0.000 claims description 18
- 230000001605 fetal effect Effects 0.000 claims description 15
- 241000700721 Hepatitis B virus Species 0.000 claims description 13
- 210000000952 spleen Anatomy 0.000 claims description 11
- 238000012753 partial hepatectomy Methods 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 7
- 210000003240 portal vein Anatomy 0.000 claims description 6
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 claims description 5
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 210000005228 liver tissue Anatomy 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 102000001183 RAG-1 Human genes 0.000 claims description 4
- 108060006897 RAG1 Proteins 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 abstract description 4
- 241001442539 Plasmodium sp. Species 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 43
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000002458 infectious effect Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 238000010171 animal model Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 208000037262 Hepatitis delta Diseases 0.000 description 4
- 241000724709 Hepatitis delta virus Species 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 210000004258 portal system Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000009594 Animal Hepatitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010011008 Chalones Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- WMTIOGUVKBSEOW-UHFFFAOYSA-N ClC1(Cl)OP(=O)OP(=O)O1 Chemical compound ClC1(Cl)OP(=O)OP(=O)O1 WMTIOGUVKBSEOW-UHFFFAOYSA-N 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 206010035660 Pneumocystis Infections Diseases 0.000 description 1
- 208000025598 Pneumocystis infectious disease Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- -1 drugs Chemical class 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the field of this invention is immunocompromised mammals comprising xenogeneic hepatocellular tissue.
- the liver is a critically important organ for monitoring and adjusting plasma constituents.
- Hepatocytes are active in controlling levels of blood glucose, lipids and cholesterol, and a number of plasma proteins.
- the plasma proteins include albumin, fibrinogen and prothrombin, and several complement factors.
- the structure of a liver lobule is that of a hexagon with portal triads at each corner, where each triad contains branches of the hepatic portal vein, hepatic artery and bile duct, so that each hepatocyte is in a close association with the vascular system.
- Hepatocytes synthesize triglycerides, cholesterol and phospholipids. Much of the lipid synthesized is then packaged with proteins and released into the circulation as VLDLs, providing a source of fatty acids for all cells. Hepatocytes also synthesize the enzyme essential for formation of cholesteryl esters in HDL, remove chylomicron fragments from the circulation, and are an indirect source of LDLs, which are formed in plasma from VLDLs depleted of fatty acids. Balancing the lipoprotein levels and cholesterol content in the circulation has proven to be a critical factor in vascular disease.
- Glucose from the blood is stored by hepatocytes in the form of glycogen. This is a major source of glucose for other cells in the body. During meals with high glucose, insulin increases the ability of hepatocytes to synthesize glycogen. As blood glucose drops, glucagon and epinephrine increase the ability of hepatocytes to degrade glycogen. Enzyme deficiencies associated with glycogen deficiencies can result in storage diseases.
- liver has a unique regenerative capacity. After partial hepatectomy, the liver mass is restored by division of fully differentiated hepatocytes. Even in adults, these cells have a tremendous replicative ability. The existence of liver stem cells remains controversial, but such cells may be active in liver growth after severe injury.
- hepatocytes The response of hepatocytes to tissue damage is mediated by several cytokines.
- cytokines such as epidermal growth factor (EGF), tumor growth factor (TGFa), and hepatocyte growth factor (HGF).
- EGF epidermal growth factor
- TGFa tumor growth factor
- HGF hepatocyte growth factor
- HBV human hepatitis B virus
- the only animals that can be infected with human hepatitis B virus (HBV) are humans and chimpanzees, and the major tissue that is productively infected is the liver, althou there have been reports of infected stromal cells.
- HBV human hepatitis B virus
- Primary hepatocyte cultures are susceptible to infection for only a few days, if at all, and do not produce the characteristic infectious particles.
- Human hepatitis D virus (HDV) requires envelope proteins produced by HBV, and therefore can only infect cells susceptible to HBV. The need for a good experimental system having cells that are susceptible to productive infection by viruses such as the hepatitis viruses, and other hepatic pathogens, remains.
- the field of medicine relies heavily on animal models. These models provide a means of analyzing the effect of viruses and other pathogens, cytokines, environmental factors, hormones, diet, and the like. Without animal models, it is extremely difficult to perform controlled experiments. Having viable human tissue in an animal model provides numerous advantages. One can investigate the effect of agents on the tissue at various stages in the development of the disease. The interactions of cells, secreted agents and tissue can also be analyzed. A xenogeneic animal model further provides a means of testing the effect of factors and other agents on cells that are difficult to maintain in culture. Short-lived lymphocyte subsets, neural cells, complex tissues, neutrophils, etc. that cannot easily be grown in culture for extended periods of time may be examined.
- hepatocyte stimulatory effect of FK506 is described in Sakata et al. (1994) Int. Hepatol Commun. 2:67-69.
- Hepatic cell transplantation in the mouse is disclosed in Rhim et al. (1994) Science 263:1149-1152.
- the in vivo response of hepatocytes to growth factors is discussed in Webber et al. (1994) Hepatol 19:489-497.
- Engraftment of hepatocytes after intra-splenic injection is described in Gupta et al. (1991) Hepatologv 14:144-149.
- the growth of liver cells in the pancreas after intra-splenic transplantation is discussed in Jaffe et al. (1991) Int.
- Immunocompromised non-human mammalian hosts comprising functional human hepatocytes.
- Isolated human hepatocytes or fragments of human hepatic tissue are introduced into the xenogeneic host at a site that permits survival of the cells, in conjunction with hepatocyte growth factors.
- the hepatocytes are able to survive and function in the host animal.
- the chimeric animal has broad applicability in the study of human hepatic diseases.
- the chimeric animal has broad applicability in the study of human infectious diseases with hepatocellular tropism, degenerative and metabolic diseases of the human liver, and toxic or carcinogenic agents that target the human liver.
- Methods and compositions are provided for the growth of hepatocytes in an immunocompromised heterologous mammalian host, particularly a mouse, for extended periods of time.
- the method comprises implanting isolated human hepatocytes in an appropriate site in an immunocompromised host, in conjunction with growth factors.
- the chimeric animal provides an easily manipulated experimental model that is useful for studying human hepatic diseases.
- Hepatocytes are isolated from human liver tissue by any convenient method, as known in the art.
- the liver tissue is dissociated mechanically or enzymatically to provide a suspension of single cells.
- fragments of intact human hepatic tissue may be used.
- the suspension may be enriched for hepatic precursors by Ficoll-hypaque density gradient centrifugation, fluorescence activated cell sorting, panning, magnetic bead separation, elutriation within a centrifugal field, or rosetting.
- a suspension of partially purified hepatocytes usually at least about 50% hepatocytes by number, more usually at least about 80% hepatocytes by number, is used for implantation.
- the ability of hepatocytes to engraft is increased by providing growth factors involved in liver regeneration.
- the factors may be administered from an exogenous source, or expression may be induced in the animal host.
- Factors that increase proliferation of hepatocytes include insulin, epidermal growth factor (EGF), tumor growth factor a (TGFa) and hepatocyte growth factor (HGF), as well as a wide variety of factors produced by the gut, pancreas and liver.
- the factors may be administered singly, particularly HGF, or as a cocktail.
- Preferably human factors will be used, although cross- reactive factors from other species may be used in place of human. Administration may be through any convenient method, e.g.
- the animal host may be stimulated to produce growth factors by a partial hepatectomy. Removal of one-third to two-thirds of the host liver provides adequate hepatocyte growth factors for engraftment. These factors may be those previously characterized, as well as chalones, a class of molecules believed to be responsible for liver regeneration.
- the hepatocyte growth factors produced by partial hepatectomy of the animal host are sufficiently active on human hepatocytes to provide for engraftment.
- the site of implantation is important for successful engraftment of hepatocytes, such that the liver cells will be placed in contact with the host growth factors, nutrients, and other factors required by the human hepatocytes. For the most part, factors regulating the total functional liver mass are thought to originate in the intestine and pancreatic epithelium, and are transported to the liver via the hepatic portal system.
- a suspension of hepatocytes is injected into a suitable acceptor organ, where the cells are able to engraft.
- Organs that can be seeded with hepatocytes include the spleen and liver. The liver may be directly seeded by injection into the portal vein. Injection into one organ may result in translocation of cells to the other organs.
- intrasplenic implantation which allows the injected hepatocytes to seed the splenic parenchyma or home to the liver stroma via the hepatic portal system.
- pieces of intact hepatic tissue may be implanted directly into the host liver, or isolated hepatocytes injected directly into the host liver.
- the cells After injection of the donor hepatocytes, the cells engraft in the host liver, pancreas and/or spleen.
- the engrafted cells may be either randomly distributed in the host liver, or grow as discrete acini.
- the hepatic cells may be used after at least about 2 weeks and will remain functional for at least about 6 weeks, or more.
- the engrafted hepatocytes are functional.
- Assays for function may include responsiveness to insulin and glucagon, the ability to produce liver specific proteins, e.g. human serum albumin, c- reactive protein in response to IL-6, and the like.
- the chimeric animal provides an environment for the introduction of a number of agents that are suspected of causing or contributing to hepatic disease, as well as the appropriate antagonists and blocking agents.
- the human hepatocytes may be fresh tissue, obtained within about 48 hours of death, or freshly frozen tissue, tissue frozen within about 12 hours of death and maintained at below about -10°C, usually at about liquid nitrogen temperature (- 120°C) indefinitely. Normally the tissue will not have been subject to culture in vitro for an extended period of time.
- the donor tissue will be human, although cells from sources other than members of the same family as the host animal may find use.
- the source of the tissue will usually be fetal.
- the tissue will be from a child of less than about 3 years, preferably less than about 1 year and at or younger than neonate, more preferably being fetal tissue of from about 7 to 24 weeks. In some cases adult human hepatocytes may be implanted.
- the tissue will generally be normal, e.g. non-transformed and non-malignant, except in those cases where study of a particular malignancy is desired.
- Immunocompromised mammalian hosts suitable for implantation and having the desired immune incapacity exist or can be created.
- the significant factor is that the immunocompromised host is incapable naturally, or in conjunction with the introduced organs, of mounting an immune response against the xenogeneic tissue or cells. Therefore it is not sufficient that a host be immunocompromised, but that the host may not be able to mount an immune response after grafting, as evidenced by the inability to produce functional syngeneic host B-cells, particularly plasma cells, and/or T-cells, particularly CD4 + and/or CD8 + T-cells after implantation.
- B-cells particularly plasma cells
- T-cells particularly CD4 + and/or CD8 + T-cells after implantation.
- small mammals e.g.
- murines e.g. mouse and rat, which are immunocompromised due to a genetic defect which results in an inability to undergo germline DNA rearrangement at the loci encoding immunoglobulins and T-cell antigen receptors.
- mice that have been genetically engineered by transgenic disruption to lack the recombinase function associated with RAG-1 and/or RAG-2 (e.g. commercially available TIMTM RAG-2 transgenic), to lack Class I and/or Class II MHC antigens (e.g. the commercially available CID and C2D transgenic strains), or to lack expression of the Bcl-2 proto-oncogene.
- RAG-1 and/or RAG-2 e.g. commercially available TIMTM RAG-2 transgenic
- Class I and/or Class II MHC antigens e.g. the commercially available CID and C2D transgenic strains
- Bcl-2 proto-oncogene e.g. the commercially available mice that have a homozygous mutation at the scid locus, causing a severe combined immunodeficiency which is manifested by a lack of functionally recombined immunoglobulin and T-cell receptor genes.
- the scid/scid mutation is available or may be bred into a number of different genetic backgrounds, e.g. CB.17, ICR (outbred), C3H, BALB/c, C57B1/6, AKR, BA, BIO, 129, etc.
- Other mice which are useful as recipients are NOD scid/scid; SGB scid/scid, bh/bh; CB.17 scid/hr; NIH-3 bg/nu/xid and META nu/nu.
- Transgenic mice, rats and pigs are available which lack functional B cells and T cells due to a homozygous disruption in the CD3e gene.
- Immunocompromised rats include HsdHan:RNU-r « «; HsdHan:RNU-rm//+; HsdHan:NZNU-rm.; HsdHa NZNU- rnu/+; LEW/HanHsd-r « «; LEW/HanHsd-rn «/+; WAG/HanHsd-r»« and WAG/HanHsd- rnu/+.
- Additional loss of immune function in the host animal may be achieved by decreasing the number of endogenous macrophages before, during, or after implantation of the xenogeneic tissue.
- reduction of macrophages by administration of dichloromethylene diphosphonate (Cl-MDP) encapsulated in liposomes, as described in co-pending application no. 08/169,293.
- the host will usually be of an age less than about 25% of the normal lifetime of an immunocompetent host, usually about 1 to 20% of the normal lifetime. Generally, the host will be at least about four weeks old and large enough to manipulate for introduction of the donor tissue at the desired site. For example, mice are usually used at about 4 to 6 weeks of age. Growth of the tissue within the host will vary with the organ.
- the mammalian host will be grown in conventional ways. Depending on the degree of immunocompromised status of the mammalian host, it may be protected to varying degrees from infection. An aseptic environment is indicated. Prophylactic antibiosis for protection from Pneumocystis infection may be achieved for scid/scid mice with 25-75 mg trimethoprim and 100-300 mg sulfamethoxazole in 5 ml of suspension, given three days each week, or in impregnated food pellets. Alternatively, it may be satisfactory to isolate the potential hosts from other animals in gnotobiotic environments after cesarean derivation. The feeding and maintenance of the chimeric host will for the most part follow gnotobiotic techniques.
- tissue may be transplanted into the host in addition to the hepatocytes.
- hematopoietic components may be included, such as stem cells, lymph nodes, embryonic yolk sac, fetal liver, pancreatic tissue, appendix tissue, tonsil tissue and the like, which may serve to provide human lymphoid and granulocytic cells in the immunocompromised host.
- Sites for introduction of additional tissue may include under the spleen capsule, abdominal wall muscle, under the renal capsule, in the anterior chamber of the eye, the peritoneum, the peritoneal lining, brain, subcutaneous, vascular system, spinal cord, membranous sacs or capsules of various tissue, the retroperitoneal space, reproductive organs, ear pinnae, etc.
- tissue or cells of interest will generally be normal, e.g. non-transformed and non-malignant tissue or cells.
- tissue or cells of interest will generally be normal, e.g. non-transformed and non-malignant tissue or cells.
- the surrounding tissue may comprise connective tissue, or portions of blood and lymphatic vessels.
- whole organ grafts may be transplanted by anastomosing donor and host blood vessels, lymphatic vessels, and the like.
- normal cells, tissue, and/or organs may be stably maintained and functional for at least about 3-6 months and frequently for at least about 10 months.
- a mixed population of cells in suspension may be enriched for the particular cells of interest.
- the suspension may be enriched for T cells by Ficoll-hypaque density gradient centrifugation, fluorescence activated cell sorting, panning, magnetic bead separation, elutriation within a centrifugal field, or rosetting.
- Immunoaffinity columns may be employed which allow for specific separation of either the desired or undesired cells, depending on the antibodies or fragments thereof used for separation, and the nature of the mixture.
- dispersed cells are employed, where the relevant organs are teased apart to yield viable cells in suspension.
- Cells of particular interest as a secondary implant are human hematopoietic cells, particular T cells, neutrophils, and other granulocytic and myeloid cells. Such cells may be obtained from an immunocompetent human donor.
- the hematopoietic cells may be mismatched as to HLA type with the hepatocytes, so as to provide a marker for the source, or may be matched as to HLA type in order to provide T cells that recognize antigen presented by the hepatocytes.
- the presence of the human hepatocytes in an immunocompromised host may be used to study the effect of various compounds on the growth, viability, differentiation, maturation, transformation, or the like, of the human cells in a live host.
- the chimeric host may be used to study the effect of a variation of a condition on a symptom or indication of a disease.
- condition it is intended a physical, chemical or biological property, e.g. temperature, electric potential, ionic strength, drugs, transformation, etc.
- hepatic pathogens e.g. viruses, protozoans and bacteria
- drugs and toxins e.g. isoniazid, carbon tetrachloride, and ethanol.
- the effect of such agents of human hepatocellular tissue may be investigated with the subject animals.
- Viruses of interest include the human hepatitis viruses A, B, C, D and E, particularly HBV and HDV, which cannot be grown in culture.
- Other hepatic viruses are Epstein-Barr virus, cytomegalovirus, varicella-zoster virus and yellow fever viruses. Infection of hepatocytes is an essential feature of Plasmodium falciparum, P. vivax, P. ovale and P. malariae infection. The worldwide incidence of malaria provides a strong incentive for the study of its disease etiology.
- the pathogen may be wild-type, e.g. clinical isolates, conventional strains, etc.; attenuated strains; or may be genetically engineered to enhance or reduce infectivity, pathogenicity, etc.
- modifications in the genome may include deletion of virulence genes, mutations in coat proteins that alter the host range, change in viral nucleic acid polymerases, alterations in proteins that affect integration into the host genome, etc. Mutations introduced into the pathogen genome are useful to map the functions of various proteins, and to determine which domains are responsible for various aspects of the infection, i.e. in establishing latency, transforming cells, replication, etc.
- a liver implant is inoculated with the pathogen, usually at an infectious level.
- the effect of the pathogen is determined, in most cases as a function of time.
- Data may be obtained as to the response of human cells to the pathogen; products which are secreted by infected or involved cells in response to infection, e.g. cytokines, interferons, etc.; the viability and growth of the human hepatocytes; and pathogen replication, e.g. release of new infectious particles or cells.
- Infection may be achieved by direct injection of the pathogen.
- the injection will involve at least about 10 2 infectious units, preferably from about 10 3 to 10 5 infectious units.
- the pathogen may be a clinical isolate, a cloned clinical isolate, a genetically modified isolate, or the like.
- administration may be via injection of infected cells, where the injected cells will produce infectious pathogens over time.
- the cells will deliver a dose of at least about 10 2 infectious units, preferably from about 10 3 to 10 5 infectious units.
- Non-invasive techniques include NMR, CAT scans, fluoroscopy, roentgenography, radionuclide scanning, ultrasonography, electrocardiography, electroencephalography, evoked potentials, etc.
- Invasive techniques include biopsy, autopsy, laparotomy, intermittent intravenous blood sampling, or intravenous catheterization, etc. Convenient placement of various devices, e.g. catheters, electrodes, etc. may be performed for continuous monitoring.
- the host may be used to determine the carcinogenicity of various compounds, the effect on growth and viability of hepatic tissue, the effect of combinations of compounds, e.g. drugs, or the like.
- the effect of various drugs in protecting the host tissue from the pathogen, as well as being cytotoxic to or suppressive of the pathogen in a cellular environment can be determined.
- Use of the chimeric animal in studying the effect of drugs on infection may begin with administration of the drug prior to, substantially concomitant with, and/or subsequent to the administration of the infectious dose of pathogen.
- Administration of the drug will usually begin not earlier than 7 days prior to infection, more usually not more than about 1 day prior to infection. In most cases, administration of the drug will begin not later than about 7 days after infection, more usually not later than about 1 day after infection.
- drug treatment may be started after as much as one year after infection, usually after six months, more usually after one month. After initial screening, different periods of time may be of interest in establishing the effectiveness of the drug.
- the manner of administration will vary greatly, depending upon the nature of the drug. It may be provided orally, ad libitum, intraperitoneally, intravascularly, subcutaneously, intrathymically, or the like. Usually, different dosage levels will be employed, based on past experience with the drug, anticipated levels with human treatment, toxicity or side effects, experience with the particular chimeric host, and the like.
- the effect of the drug may be monitored for any convenient time, usually at least 1 week from the initiation of administration of the drug, more usually at least 2 weeks, and at times for periods as long as 6 weeks or more. Preferably, determinations will be made in the period from about 2-6 weeks.
- Phenotyping of the xenogeneic cells to verify their origin and stage of developmental progression may be performed by standard histological methods, by immunohistochemistry, antibody staining or in situ hybridization with RNA and/or DNA probes. The exact method is not critical to the invention.
- HLA markers may be used to distinguish the established xenogeneic organ transplants. The HLA type can be readily determined by staining with an appropriate antibody directed against any of the alleles of the human HLA locus, including Class I and Class II antigens.
- physiologic products of human hepatocytes distinguishable from their murine analogs by immunologic or quantitative criteria, e.g. expression of human serum albumin, or expression of c- reactive protein in response to IL-6, etc., can be used to determine the presence of human cells without sacrifice of the recipient.
- Placement of isolated hepatocytes into the mouse hepatic environment will provide growth factors, nutrients and other influences to the liver cells without the addition of other human tissue such as pancreas or intestine.
- Splenic injection allows injected hepatocytes the option of either proliferating into microtubules in the splenic parenchyma, or homing to the liver through the hepatic portal system.
- Partial hepatectomy induces expression of hepatic growth factors, because of the autonomous signaling that occurs following reduction in functional liver mass.
- Partial hepatectomy and splenic injection can be performed via a single surgical approach in minimal time. The transplantation was done into animals that are 4-6 week old C.B-17 scid/scid mice of either sex.
- Tissue from a 20-23 week old human fetal liver is collected into Hanks' balanced salts. 1.5 to 2 grams of the liver is minced by sharp dissection, then incubated in RPMI with 100 IU/ml type VI collagenase to enzymatically dissociate hepatocytes. All cells are pelleted at 500 x g for 10 minutes at 10°C and the connective tissue remnant discarded. The pellet is resuspended in cold RPMI.
- the resuspended pellet is centrifuged at 50 x g for 5 minutes.
- the pellet (small mononuclear cells) and supernatant (large hepatocytes in suspension) are separated, saving both fractions for later testing.
- the hepatocyte enrichment is repeated by light centrifugation of supernatant, and the second pellet resuspended in RPMI.
- the cell suspension can then be held on wet ice for up to 2 hours until injected.
- the hepatocyte yield and concentration is then checked visually by Wright-Giemsa staining, and the cell viability is checked by trypan-blue dye exclusion.
- the cell suspension for injection is prepared from the fraction with the highest concentration of hepatocytes.
- the fraction with the highest hepatocyte concentration is resuspended in normal saline for injection.
- the dose is calculated by the number of mice to be injected x 0.1 ml per injection.
- An optimal injection dose is 10* to 10 7 viable hepatocytes per injection.
- a 28 gauge needle attached to a 0.5 ml tuberculin syringe is used for injections.
- the cell suspension is transported to surgery in ice.
- Mice are anesthetized with either metafane using an open-drop method, or ketamine/xylazine cocktail using an intramuscular injection.
- the lateral abdomen is clipped and prepared for surgery.
- a left lateral paracostal abdominal incision is made over the normal position of the spleen.
- the left caudate lobe of the liver is located and exteriorized through the incision, making sure that the stomach, pancreas, proximal duodenum and biliary tract are not pulled or handled.
- the base of the lobe is elevated and ligated with 6-0 Vicryl or other absorbable suture.
- the ligature is tightened with multiple surgical knots.
- the lobe is transected by sharp dissection, and the exposed liver surface packed with sterile gel-foam. After holding the stump briefly to be certain of hemostasis, it is returned to the abdomen. The spleen is carefully located and exteriorized through the incision without disrupting any mesenteric or vascular attachments. 0.1 ml of the hepatocyte suspension is injected with a 28 guage needle, which punctures the splenic capsule on its antimesenteric surface.
- the needle should be parallel to the long axis of the spleen.
- the spleen is returned to the abdominal cavity, and the body wall closed with one or two simple interrupted sutures using 5-0 or 6-0 Vicryl, followed by a steel clip closure of the skin incision.
- liver fragments are implanted. Tissue from a 20-23 week old human fetal liver is cut with a sharp blade into approximately l l x l mm pieces. The mice are anesthetized and a 1 cm incision made in the liver at a site separate from the hepatectomy. One or two of these fragments are implanted with an 18 gauge trocar.
- Animals are held in recovery and observed to rouse from anesthesia, and then checked every 24 hours for 3 days post-surgery. Starting at two weeks post surgery, blood samples may be collected for screening.
- Serum samples are collected to screen for the success of engraftment by human hepatocytes.
- the samples are tested for the presence of human albumin (produced solely by hepatocytes) by RIA.
- Human albumin produced solely by hepatocytes
- Polyclonal anti-human serum albumin is commercially available (United States Biochemical).
- the antisera may be cleared of mouse cross-reactive antibodies by affinity purification against mouse serum albumin.
- spleens and livers are removed and fixed in 10% neutral buffered formalin (10% formalin in phosphate or carbonate buffer, pH 7.4) following collection of heart blood. Following fixation, tissues are processed for histologic and immunohistologic examination. Immunostaining is performed using rabbit a-human HLA (pan class I) antibody on formalin fixed, dewaxed sections, with secondary staining with FITC or peroxidase conjugated goat a-rabbit IgG.
- HLA pan class I
- Hepatic cells derived from diseased liver may be introduced into previously implanted liver grafts to study malignancy and the effects of growth factors and/or drugs which might modulate normal liver function or disease states.
- this model can also serve as a valuable system to test the long-term expression of exogenous genes introduced into human hepatic cells.
- the model is also a valuable system for observing the effects of human tropic viral infection and therapy in an in vivo system. It provides an alternative to animal hepatitis viruses and in vitro culture for the investigation of hepatocellular function during acute and/or chronic infection.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62229/96A AU6222996A (en) | 1995-06-07 | 1996-06-06 | Human hepatocellular tissue in chimeric immunocompromised an imals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47524295A | 1995-06-07 | 1995-06-07 | |
US08/475,242 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996039810A1 true WO1996039810A1 (en) | 1996-12-19 |
Family
ID=23886788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/002456 WO1996039810A1 (en) | 1995-06-07 | 1996-06-06 | Human hepatocellular tissue in chimeric immunocompromised animals |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6222996A (en) |
WO (1) | WO1996039810A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999016307A1 (en) * | 1997-09-26 | 1999-04-08 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis c virus |
WO1999060846A1 (en) * | 1998-05-26 | 1999-12-02 | Innogenetics N.V. | Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies |
WO2000040083A1 (en) * | 1999-01-05 | 2000-07-13 | Surrogen, Inc. | Chimeric animal with engrafted xenogeneic tissue and method for producing same |
WO2001005955A2 (en) * | 1999-07-14 | 2001-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Animals comprising human hepatocellular tissue |
WO2001032009A1 (en) * | 1999-11-02 | 2001-05-10 | The University Of Connecticut | Propagation of human hepatocytes in non-human animals |
US6995299B2 (en) | 1999-11-02 | 2006-02-07 | University Of Connecticut | Propagation of human hepatocytes in non-human animals |
EP1784640A2 (en) * | 2004-08-20 | 2007-05-16 | KMT Hepatech, Inc. | Malarial animal model having a chimeric human liver |
US7498479B2 (en) | 2000-03-17 | 2009-03-03 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018144A1 (en) * | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
WO1994002601A1 (en) * | 1992-07-24 | 1994-02-03 | The Trustees Of The University Of Pennsylvania | Non-native liver generation in an animal with impaired native liver function by cell implantation |
WO1995009235A1 (en) * | 1993-09-28 | 1995-04-06 | Albert Einstein College Of Medicine Of Yeshiva University | Immunodeficient mouse models of pathogenesis of human disease and efficacy and toxicity of disease treatments |
-
1996
- 1996-06-06 AU AU62229/96A patent/AU6222996A/en not_active Abandoned
- 1996-06-06 WO PCT/EP1996/002456 patent/WO1996039810A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018144A1 (en) * | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
WO1994002601A1 (en) * | 1992-07-24 | 1994-02-03 | The Trustees Of The University Of Pennsylvania | Non-native liver generation in an animal with impaired native liver function by cell implantation |
WO1995009235A1 (en) * | 1993-09-28 | 1995-04-06 | Albert Einstein College Of Medicine Of Yeshiva University | Immunodeficient mouse models of pathogenesis of human disease and efficacy and toxicity of disease treatments |
Non-Patent Citations (2)
Title |
---|
RIVAS ET AL: "TRANSPLANTATION OF HEPATOCYTES: AN IN-VITRO AND IN-VIVO STUDY IN CANINES", CELL TRANSPLANTATION, vol. 3, no. 2, 1994, pages 193 - 201, XP000603963 * |
SANHADJI ET AL: "FETAL LIVER CELL TRANSPLANTATION IN VARIOUS MURINE MODELS", BONE MARROW TRANSPLANTATION, vol. 9, no. S1, 1992, pages 77 - 82, XP000603962 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999016307A1 (en) * | 1997-09-26 | 1999-04-08 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis c virus |
US6034297A (en) * | 1997-09-26 | 2000-03-07 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis C virus |
WO1999060846A1 (en) * | 1998-05-26 | 1999-12-02 | Innogenetics N.V. | Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies |
WO2000040083A1 (en) * | 1999-01-05 | 2000-07-13 | Surrogen, Inc. | Chimeric animal with engrafted xenogeneic tissue and method for producing same |
US6660905B1 (en) | 1999-07-14 | 2003-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Mice comprising engrafted functional human hepatocytes |
WO2001005955A3 (en) * | 1999-07-14 | 2001-08-16 | Univ Leland Stanford Junior | Animals comprising human hepatocellular tissue |
WO2001005955A2 (en) * | 1999-07-14 | 2001-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Animals comprising human hepatocellular tissue |
WO2001032009A1 (en) * | 1999-11-02 | 2001-05-10 | The University Of Connecticut | Propagation of human hepatocytes in non-human animals |
US6525242B1 (en) | 1999-11-02 | 2003-02-25 | The University Of Connecticut | Propagation of human hepatocytes in non-human mammals |
US6995299B2 (en) | 1999-11-02 | 2006-02-07 | University Of Connecticut | Propagation of human hepatocytes in non-human animals |
US7498479B2 (en) | 2000-03-17 | 2009-03-03 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver |
US7781642B2 (en) | 2000-03-17 | 2010-08-24 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US8212106B2 (en) | 2000-03-17 | 2012-07-03 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US8445745B2 (en) | 2000-03-17 | 2013-05-21 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
EP1784640A2 (en) * | 2004-08-20 | 2007-05-16 | KMT Hepatech, Inc. | Malarial animal model having a chimeric human liver |
EP1784640A4 (en) * | 2004-08-20 | 2010-10-06 | Kmt Hepatech Inc | Malarial animal model having a chimeric human liver |
Also Published As
Publication number | Publication date |
---|---|
AU6222996A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100656795B1 (en) | Chimeric animal model susceptible to human hepatitis c virus infection | |
EP0481058B1 (en) | Human lymphoid tissue in an immunocompromised host | |
JPH0231632A (en) | Chimera-oriented immune unguarded animal and use thereof | |
US5663481A (en) | Animal model of the human immune system | |
US20100115642A1 (en) | Xenogenic immune system in a non-human mammal | |
JP4403200B2 (en) | Animal model of the human immune system and method for creating it | |
AU676194B2 (en) | Non-native liver generation in an animal with impaired native liver function by cell implantation | |
WO1996039810A1 (en) | Human hepatocellular tissue in chimeric immunocompromised animals | |
US6660905B1 (en) | Mice comprising engrafted functional human hepatocytes | |
US6455756B1 (en) | Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice | |
US5602305A (en) | Immunodeficient animal model for studying T cell-mediated immune | |
US5434341A (en) | Xenogeneic lymph node in mammary fat pad | |
WO2004110139A1 (en) | Process for producing human-origin immunocompetent cell | |
Abele-Ohl et al. | Rag2−/− γ-chain−/− mice as hosts for human vessel transplantation and allogeneic human leukocyte reconstitution | |
WO2005067709A2 (en) | Chimeric murine model comprising human hepatocytes user for screening compounds | |
US20210251199A1 (en) | Non-human vertebrate comprising human liver cells transplanted therein and method for producing the same | |
US5516977A (en) | Xenogeneic tissue implant in ear pinna | |
US20080104720A1 (en) | Animal Models for Cell Therapy and Cell Based Gene Therapy | |
Amiezer | Regulation of Mucosal Immune Responses by the IgA Cytoplasmic Tail | |
JP2007521025A (en) | Non-human mammal model containing heterologous nucleated cells, use for screening compounds | |
Wang et al. | TIPE2-modified human amnion-derived mesenchymal stem cells promote the efficacy of allogeneic heart transplantation through inducing immune tolerance | |
Renna | The role of antigen receptor isotype in B cell development, humoral response and tolerance | |
EP1474682A2 (en) | Production of human antibodies in immunodeficient, non-human, mammalian hosts | |
EP0787003A2 (en) | Use of macrophage depleting agents for prolonging the survival of non-autologus hematopoietic cell transplants and animal model assay systems | |
King | The Humanized Mouse Model: The Study of the Human Alloimmune Response: A Dissertation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |